Influenza virus vaccine - Vaccitech

Drug Profile

Influenza virus vaccine - Vaccitech

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Vaccitech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 09 Nov 2016 Vaccitech initiates the RIVET trial for Influenza virus infections
  • 19 Oct 2016 Vaccitech plans a phase IIb trial for Influenza virus infections (Prevention) in United Kingdom
  • 10 May 2016 Phase-II clinical trials in Influenza virus infections (Prevention) in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top